Good news comes in pairs for Holy Stone Healthcare! Holy Stone Healthcare’s Hsinchu Plant has passed GMP pilot plant evaluation, and “The new drug development plan of the new compound IBD98-M on inflammatory bowel diseases” was also granted subsidies after passing the review screening.
Holy Stone Healthcare Co., Ltd. is set to list on Taiwan’s emerging stock market on December 13.
Holy Stone Healthcare invests the pilot GMP plant
In line with Government policy to promote the biotech industry, providing the Company’s testing drug required for clinical trials, Holy Stone Healthcare Co., Ltd. (Holy Stone Healthcare) acquired qualification of a "Biotech and New Pharmaceutical company" by the Ministry of Economic Affairs in August 2011. It also passed a review conducted by the Hsinchu Science Park, and has officially stationed at the Hsinchu Biomedical Science Park in January 2012. Holy Stone Healthcare will begin its c-GMP pilot plant for software and hardware construction with expected completion date of 2013 for Taiwan and U.S. FDA inspection on GMP to prepare for testing new drugs required for clinical trials.
Holy Stone Healthcare - Certified “Biotech and New Pharmaceutical company"